Neridronic acid for the treatment of bone metabolic diseases

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 10, 2009, Pages 1305-1311

  Gatti, Davide ^a   Viapiana, Ombretta ^a   Idolazzi, Luca ^a   Fracassi, Elena ^a   Adami, Silvano ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Algodystrophy; Bisphosphonates; Osteogenesis imperfecta; Osteoporosis; Paget disease of bone

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CLODRONIC ACID; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; HYDROXYPROLINE; IBANDRONIC ACID; INTERLEUKIN 6; NERIDRONIC ACID; NITROGEN; OSTEOCALCIN; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ALGODYSTROPHY; ANGIOGENESIS; AVASCULAR NECROSIS; BIOCHEMISTRY; BONE DENSITY; BONE METASTASIS; BONE MYELOMA; BONE REMODELING; BONE TISSUE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CANCER CELL; CELL PROLIFERATION; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE SEDIMENTATION RATE; FEMUR SUBTROCHANTERIC FRACTURE; FLU LIKE SYNDROME; FRACTURE; HOME CARE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; INJECTION SITE PAIN; JAW OSTEONECROSIS; METABOLIC BONE DISEASE; MYALGIA; MYELOMA; NURSE; OSTEOARTHRITIS; OSTEOBLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TUBERCULOUS SPONDYLITIS; VULVA CARCINOMA;

ADULT; BONE DISEASES, METABOLIC; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; HUMANS; INFANT; INFANT, NEWBORN; ITALY; OSTEITIS DEFORMANS; OSTEOGENESIS IMPERFECTA;

EID: 70349383181     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903029190     Document Type: Review

References (43)

1. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-627
2. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589
3. Corrado A, Cantatore FP, Grano M, Colucci S. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol 2005;24:527-534 (Pubitemid 43055047)
4. Spreafico A, Frediani B, Capperucci C, et al. Anabolic effects and inhibition of interleukin 6 production induced by neridronate on human osteoblasts. Reumatismo 2006;58(4):288 (Pubitemid 46795028)
5. Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treat Rev 2005;31(Suppl 3):1-8, 134s-6230s
6. Ribatti D, Nico B, Mangieri D, et al. Neridronate inhibits angiogenesis invitro and invivo. Clin Rheumatol 2007;26(7):1094-1098 (Pubitemid 46863951)
7. Muller S, Migianu E, Lecouvey M, et al. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells invitro. Anticancer Res 2005;25(4):2655-2660 (Pubitemid 41044643)
8. Cepollaro C, Gonnelli S, Pondrelli C, et al. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters. Calcif Tissue Int 1999;65(2):129-132 (Pubitemid 29350650)
9. Braga V, Gatti D, Rossini M, et al. Bone turnover markers in patients with osteogenesis imperfecta. Bone 2004;34(6):1013-1016 (Pubitemid 38749238)
10. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952 (Pubitemid 28455096)
11. Munns CFJ, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005;20:1235-1243 (Pubitemid 40863813)
12. Land C, Rauch F, Munns CF, et al. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006;39:901-906 (Pubitemid 44311714)
13. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3years of age. J Clin Endocrinol Metab 2000;85:1846-1850 (Pubitemid 32269287)
14. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006;21:132-140 (Pubitemid 43023235)
15. Chevrel G, Schott A, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 2006;21:300-306 (Pubitemid 43265296)
16. Rauch F, Munns C, Land C, et al. Risedronate in the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. J Bone Miner Res 2009 [Epub ahead of print]
17. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. J Bone Miner Res 2005;20:758-763 (Pubitemid 40571632)
18. Antoniazzi F, Zamboni G, Lauriola S, et al. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 2006;149:174-179 (Pubitemid 44128547)
19. Adami S, Gatti D, Colapietro F, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003;18:126-130 (Pubitemid 36008347)
20. Gatti D, Viapiana O, Lippolis I, et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res 2005;20:1323-1326 (Pubitemid 41033515)
21. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142-148 (Pubitemid 46032607)
22. Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with neridronate in Paget's disease. Clin Exp Rheum 2002;20:55-58 (Pubitemid 34213733)
23. Filipponi P, Cristallini S, Policani G, et al. Paget's disease of bone: benefits of neridronate as a first treatment and in cases of relapse after clodronate. Bone 1998;23:543-548 (Pubitemid 28529459)
24. Merlotti D, Gennari L, Martini G, et al. Effetti della terapia endovenosa con zoledronato o neridronato in pazienti affetti da malattia ossea di Paget non-responders al pamidronato. Clin Cases Min Bone Metab 2006;3:379-380
25. Braga V, Gatti D, Colapietro F, et al. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone 2003;33:342-345 (Pubitemid 37114940)
26. Cascella T, Musella T, Orio F, etal. Effects of neridronate treatment in elderly women with osteoporosis. J Endocrinol Invest 2005;28:202-208 (Pubitemid 43162765)
27. Adami S, Gatti D, Bertoldo F, et al. Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcif Tissue Int 2008;83(5):301-307
28. Benucci M, Dolenti S, Saviola G, Manfredi M. Modificazioni dei marcatori di rimodellamento osseo in pazienti trattati con neridronato per osteoporosi indotta da glucocorticoidi. Recent Progr In Med 2006;97:24-27
29. Saviola G, Benucci M, Baiardi P, et al. Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids. Clin Exp Rheumatol 2009 In press
30. Morabito N, Gaudio A, Lasco A, et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 2004;19:1766-1770 (Pubitemid 41103426)
31. Magno C, Anastasi G, Morabito N, et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol 2005;47(5):575-580 (Pubitemid 40521898)
32. Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997;56(3):201-204 (Pubitemid 27144208)
33. Varenna M, Zucchi F, Ghiringhelli D, et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 2000;27:1477-1483 (Pubitemid 30354048)
34. La Montagna G, Malesi D, Tirri R, Valentini G.Successful neridronate therapy in transient osteoporosis of the hip. Clin Rheumatol 2005;24(1):67-69 (Pubitemid 40214804)
35. Corrado A, Quarta L, Errico S, Cantatore FP. Successful treatment of avascular bone necrosis of the knee with neridronate: a case report. Rheumatol Int 2007;27(9):891-893 (Pubitemid 46906640)
36. Quarta L, Corrado A, Melillo N, et al. Combined effect of Neridronate and specific antibiotic therapy in a case of tuberculous spondylodiscitis. Rheumatol Int 2008;28(5):495-498 (Pubitemid 351629479)
37. Mazzantini M, Di Munno O, Metalli MR, et al. R. Single infusion of neridronate (6-amino-1-hydroxy-hexylidene-1,1-bisphosphonate) in patients with active rheumatoid arthritis: Effects on disease activity and bone resorption markers. Aging Clin ExpRes 2002;14:197-201
38. Pittari G, Costi D, Raballo M, et al. Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma. Acta Biomed 2006;77:81-84 (Pubitemid 44884937)
39. O'Rourke NP, McCloskey EV, Rosini S, etal. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994;69:914-917 (Pubitemid 24140674)
40. Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41(6):326-331
41. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review [review]. Am J Med 2009;122(2 Suppl):S33-45
42. Goh S, Yang K, Koh J, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy. J Bone Joint Surg Br 2007;89:349-353 (Pubitemid 46563912)
43. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005;165:346-347 (Pubitemid 40216293)